The management of diabetes in elderly patients has many nuances that are important to the pharmacist, regardless of his or her practice setting. General guidelines and treatment modalities applied to the younger population cannot necessarily be applied to the elderly population and in most cases, should be tailored to meet their needs. The purpose of this article is to gain a better understanding of the complex nature of diabetes and management in the elderly by (1) reviewing the pathogenesis and pathophysiology of diabetes in the patients, (2) understanding complications and geriatric syndromes that may affect management of diabetes, (3) becoming familiar with nationally accepted diabetes care guidelines in the elderly, (4) reviewing recent literature pertaining to management of diabetes, and (5) reviewing medications (including newer agents) to treat diabetes in the elderly.
Distribution of age at diagnosis of diabetes among adult incident cases aged 18–79 years, United States, 2005. Centers for Disease Control Web site. Available at: http://www.cdc.gov/diabetes/statistics/age/fig1.htm. Accessed June 17, 2008
7.
RodriguezAMullerDCEngelhardtM. Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore Longitudinal Study of Aging. Metabolism Clin Exper. 2005;54:542–547.
8.
American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2008;31(suppl 1):S12–S60.
9.
HarrisMIFlegalKMCowieCC. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care. 1998;21:518–524.
10.
KnowlerWCBarrett-ConnorEFowlerSE. Reduction in the incidence of type 2 diabetes with lifestyle interventions or metformin. N Engl J Med. 2002;346:393–403.
11.
ChaissonJLJosseRGGomisR. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077.
12.
MeneillyGSHardsLTessierD. NIDDM in the elderly. Diabetes Care. 1996;19:1320–1325.
13.
MeneillyGSElliottT. Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes. Diabetes Care. 1999;22:112–118.
14.
MeneillyGSElahiD. Metabolic alterations in middle-aged and elderly lean patients with type 2 diabetes. Diabetes Care. 2005;28:1498–1499.
15.
ArnerPPollareTLithellH. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia. 1991;4:483–487.
16.
MeneillyGS. Diabetes in the elderly. Med Clin N Am. 2006;90:909–923.
17.
ShimokataHMullerDCFlegJL. Age as an independent determinant of glucose intolerance. Diabetes. 1991;40:44–51.
18.
FritscheAMadausAStefanN. Relationships among age, proinsulin, conversion, and beta-cell function in nondiabetic humans. Diabetes. 2002;51(suppl 1):S234–S239.
19.
IozzoPBec-NielsenHLaaskoM. Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab. 1999;84:863–868.
20.
FukuiMNakamuraNMizutaniT. Clinical features of elderly patients with type 2 diabetes. Diabetes Care. 1999;22:1225–1226.
21.
YatesAPLaingI. Age-related increase in haemoglobin A1c and fasting plasma glucose is accompanied by a decrease in beta cell function without change in insulin sensitivity: evidence from a cross-sectional study of hospital personnel. Diabet Med. 2002;19:254–258.
22.
ChuiKCLeeNPCohanP. Beta cell function declines with age in glucose tolerant Caucasians. Clin Endocrinol (Oxf). 2000;53:569–575.
23.
ShumizuMKawazuSTomonoS. Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance. Diabetes Care. 1996;19:8–11.
24.
MeneillyGSRyanASMinakerKS. The effect of age and glycemic level on the response of the beta-cell to glucose-dependant insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin. J Clin Endocrinol Metab. 1998;83:2925–2932.
25.
RanganathLSedgwickIMorganL. The ageing entero-insular axis. Diabetologia. 1998;41:1309–1313.
26.
ChangAMHalterJB. Aging and insulin secretion. Am J Physiol Endocrinol Metab. 2003;284:E7–E12.
27.
ForbesAElliotTTildesletH. Alterations in non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes. 1998;47:1915–1919.
28.
MeneillyGSElahiDMinakerKL. Impairment of noninsulin-mediated glucose disposal in the elderly. J Clin Endocrinol Metab. 1989;68:566–571.
29.
HaffnerSMLehtoSRonnemaaT. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234.
30.
BertoniAGKropJSAndersonGFBrancatiFL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471–475.
31.
BertoniAGKirkJKGoffDC Jr. Excess mortality related to diabetes mellitus in elderly Medicare beneficiaries. Ann Epidemiol. 2004;14:362–367.
32.
California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51:S265–S280.
33.
GrundySMBrewerBCleemanJI. Definition of the metabolic syndrome. Circulation. 2004;109:433–438.
34.
MarcusMAMurphyLPi-SunyerFX. Insulin sensitivity and serum triglyceride level in obese white and black women: relationship to visceral and truncal subcutaneous fat. Metabolism. 1999;48:194–199.
35.
ThearleMBrillantesMB. Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide activity. Curr Opin Clin Nutr Metab Care. 205;8:9–16.
36.
SinclairAJ. Special considerations in older adults with diabetes: meeting the challenge. Diabetes Spectrum. 2006;19:229–233.
37.
SinghIMarshallMC Jr. Diabetes mellitus in the elderly. Endocrinol Metab Clin North Am. 1996;24:255–272.
38.
MeneillyGSCheungETuokkoH. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes. 1994;43:403–410.
39.
BethelMASloanFABelskyD. Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. Arch Intern Med. 2007;167:921–927.
40.
KnopmanDBolandLLMosleyT. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42–48.
41.
OttAStolkRPvan HarskampF. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999;53:1937–1942.
42.
FontbonneABerrCDucimetiereP. Changes in cognitive abilities over a 4 year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care. 2001;24:366–370.
43.
MatySCFriedLPVolpatoS. Patterns of disability related to diabetes mellitus in older women. J Gerontol A Biol Sci Med Sci. 2004;59:148–153.
44.
BlaumCSOfstedalMBLangaKM. Functional status and health outcomes in older americans with diabetes mellitus. J Am Geriatr Soc. 2003;51:745–753.
45.
BlaumCS. Management of diabetes mellitus in older adults: are national guidelines appropriate?J Am Geriatr Soc. 2002;50:581–583.
46.
GodolphinW. The role of risk communication in shared decision making. BMJ. 2003;327:692–693.
47.
BarryMJ. Involving patients in medical decisions: how can physicians do better?. JAMA. 1999;282:2356–2357.
48.
KassirerJP. Incorporating patients’ preferences into medical decisions. N Engl J Med. 1994;330:1895–1896.
49.
HuangESGorawara-BhatRChinMH. Self-reported goals of older patients with type 2 diabetes mellitus. J Am Geriatr Soc. 2005;53:306–311.
50.
DursoSC. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA. 2006;296:1935–1940.
51.
HuangESGorawara-BhatRChinMH. Practical challenges of individualizing diabetes care in older patients. The Diabetes Educator. 2004;30:558–570.
52.
WolffenbuttelBHRLandgrafR. for the Dutch and German Repaglinide Study Group. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care. 1999;22:463–67.
53.
BuseJHartKMinasiL. The PROTECT Study: final results of a large multicenter postmarketing study in patients with type 2 diabetes. Precose Resolution of Optimal Titration to Enhance Current Therapies. Clin Ther. 1998;20:257–269.
54.
LebovitzHeDoleJFPatwardhanR. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280–288.
55.
AronoffSRosenblattSBraithwaiteS. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care. 2000;23:1605–1611.
56.
GoldbergRBHolveySMSchneiderJ. for the Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996;19:849–856.
57.
SimonsonDCKouridesIAFeinglosM. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Diabetes Care. 1997;20:597–606.
58.
GarberAJDuncanTGGoodmanAM. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;102:491–497.
59.
OdegardPSSetterSMNeumillerJJ. Considerations for the pharmacological treatment of diabetes in older adults. Diabetes Spectrum. 2007;20:239–247.
60.
NathanDMBuseJBDavidsonMB. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–1972.
MathieuCBollaertsK. Antihyperglycemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract. 2007;61:29–37.
63.
HolsteinAStumvollM. Contraindications can damage your health—is metformin a case in point?. Diabetologia. 2005;48:2454–2459.
64.
InzucchiSEMasoudiFAMcGuireDK. Metformin in heart failure. Diabetes Care. 2007;30:e129.
NestoRWBellDBonowRO. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941–2948.
68.
NissenSEWolskiK. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular events. N Engl J Med. 2007;356:2457–2471.
69.
SchwartzAVSellmeyerDEVittinghoffE. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349–3354.
70.
GreyABollandMGambleG. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreased bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92:1305–1310.
71.
YaturuSBryantBJainSK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007;30:1574–1576.
72.
KahnSEHaffnerSMHeiseMA. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443.
ShorrRIRayWADaughertyJR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44:751–755.
75.
RosenstockJCorraoPJGoldbergRB. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. Clin Ther. 1993;15:1031–1340.
76.
HolsteinAPlaschkeAEick-HartwigE. Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17:467–473.
77.
BrodowsRG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care. 1992;15:75–80.
78.
DraegerE. Glimepiride: clinical profile of glimepiride. Diab Res Clin Pract. 1995;28(suppl):S139–S146.
79.
BadianMKornALehrKH. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug Metabol Drug Interact. 1996;13:69–85.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
83.
ChelliahABurgeMR. Hypoglycemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging. 2004;21:511–530.
YoungAAGedulinBRBhavsarS. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys. Diabetes. 1999;48:1026–1034.
87.
EganJMClocquetARElahiD. The insulinotropic effect of acute exendin-4 administered in humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab. 2002;87:1282–1290.
88.
ParkesDGPittnerRJodkaC. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism. 2001;50:583–589.
89.
SzaynaMDoyleMEBetkeyJA. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology. 2000;141:1936–1941.
90.
NielsenLLBaronAD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs. 2003;4:401–405.
91.
XuGStoffersDAHabenerJF. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276.
92.
RaynerCKSamsomMJonesKL. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24:371–381.
93.
HolstJJ. Glucagon-like peptide-1: from extract to agent–the Claude Bernard Lecture, 2005. Diabetologia. 2006;49:253–260.
94.
MeierJJNauckMA. Incretins and the development of type 2 diabetes. Curr Diab Rep. 2006;6:194–201.
95.
ShahPVellaABasuA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4053–4059.
96.
DruckerDJNauckMA. Then incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.
97.
Byetta (exenatide) product information. Amylin Pharmaceuticals, Inc Web site. Available at: http://pi.lilly.com/us/byetta-pi/pdf. Accessed October 29, 2008
98.
DruckerDJBuseJBTaylorK. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–1250.
99.
KimDMacconellLZhuangD. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487–1493.
100.
AmoriRELauJPittasAG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206.
AhrenB. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs. 2006;15:431–442.
104.
BarnettA. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60:1454–1470.
105.
AschnerPKipnesMSLuncefordJK. for the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–2637.
106.
CharbonnelBKarasikALiuJ. for the Sitagliptin Study 020 sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2938–2943.
107.
RosenstockJBrazgRAndryukPJ. and Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–1568.
NathanDM. Finding new treatments for diabetes—how many, how fast….how good?. N Engl J Med. 2007;356:437–440.
110.
Del PratoSHeineRJKeilsonL. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care. 2003;26:2075–2080.
111.
HollanderPALevyPFinemanMS. Pramlinitide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care. 2003;26:784–790.
112.
Ramlo-HalstedBAEdelmenSV. The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clin Diabetes. 2000;18:80–85.
113.
JankaHUPleweGBuschK. Combination of oral antidiabetic agents with basal insulin alone randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc. 2007;55:182–88.
114.
Yki-JarvinenHDresslerAZiemanM. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared to bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130–1136.
115.
RiddleMCRosenstockJGerichJ. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086.
